Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Endo International plc

Endo is focused on transforming insights into life-enhancing therapies. The company develops and delivers pharmaceutical solutions for various medical needs, emphasizing specialty medicines, sterile injectables, and generics.

Metric
Company Name	Endo International plc
Symbol	ENDP
MSH ID	COM:ENDO
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	IE
Stage
Employee Count	3.10K
Website	endo.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.99B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.77B
EBITDA	472.85M
Operating Income	15.75M
Net Income	-569.08M
EPS	-2.44
Diluted EPS	-2.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.59
Operating Profit Margin	0.01
EBITDA Margin	0.16
Net Profit Margin	-0.19
Return on Equity	0.60
Return on Assets	-0.06
Return on Capital Employed	0.00

COM:ENDO

Endo

Last Close

0.29

17/09 20:00

Volume Today

39.16M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.05
P/B Ratio	-0.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple	-13.90

Metric
Days Sales Outstanding	146.88
Days Payables Outstanding
Days Inventory Outstanding	84.76
Operating Cycle	156.95
Cash Conversion Cycle	156.95
Asset Turnover	0.34

Metric
Operating Cash Flow	411.05M
Free Cash Flow	333.12M
Cash Flow to Debt	0.05
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield

Metric
Cash & Equivalents	1.51B
Accounts Receivable	-82.05M
Inventory	283.55M
Goodwill	3.20B
Debt to Capitalization	1.18
Debt to Assets	1.27
Current Ratio	1.86
Quick Ratio	1.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00
R&D to Revenue	0.05
SG&A to Revenue